Publications by authors named "Siti Nadliroh"
Circulating miR-10b, soluble urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 as predictors of non-small cell lung cancer progression and treatment response.
Lyana Setiawan Rahajuningsih Setiabudy Siti Boedina Kresno Noorwati Sutandyo Elisna Syahruddin Siti Nadliroh
Cancer Biomark
March 2024
Article Synopsis
- Despite advancements in lung cancer treatment, many cases are diagnosed late, and biomarkers like microRNA10b (miR-10b), suPAR, and PAI-1 show potential for assessing disease progression and treatment response in advanced non-small cell lung cancer (NSCLC).
- A study involving 40 advanced stage NSCLC patients revealed that high levels of miR-10b may be protective against disease progression, while elevated suPAR levels served as a risk factor for worse outcomes, and increased PAI-1 levels indicated a protective effect against poor treatment response.
- Ultimately, the results highlighted suPAR as a significant independent risk factor for the progression and poor response in NSCLC, while miR-10b was not reliable
Objective: The association between PD-1, PD-L1, and PD-L2 expression and prognosis has been extensively studied in various cancers but remained controversial in breast cancer. Besides, little is known about the prognostic value of PD-1, PD-L1, and PD-L2 upregulation or downregulation following systemic therapy (chemotherapy and hormonal therapy) in breast cancer. Therefore, we aim to investigate the change of PD-1, PD-L1, and PD-L2 expression in mRNA level after primary systemic therapy in breast cancer patients and its clinical implications.
View Article and Find Full Text PDF